|
|
|
|
Yes, all persons with hemophilia (Factor VIII, Factor IX) who receive replacement therapy should be vaccinated because there appears to be an increased risk of transmission from clotting factor concentrates that are not heat inactivated. Since adult patients have a higher likelihood of having been previously infected, prevaccination testing might be considered if shown to be cost-effective. Back to Frequently asked Questions
|
